NRx Pharmaceuticals Appoints Glenn Tyson As Its First Chief Commercial Officer Ahead Of Key Ketamine Program Launches

NRx Pharmaceuticals, Inc., a biopharmaceutical company focused on developing neuroplastic therapies for depression, PTSD, and related psychiatric conditions, has announced the appointment of Glenn Tyson as its first Chief Commercial Officer. The company is preparing for the anticipated approval of its Abbreviated New Drug Application for a preservative-free ketamine product and is taking steps to strengthen its commercial infrastructure ahead of launch.

Glenn Tyson brings a rare combination of clinical and commercial experience to the role. He began his career as a counselor, working directly with children and adults affected by psychiatric disorders and addiction. After transitioning to the pharmaceutical industry, he spent 25 years building deep expertise in commercialization, sales, and strategic product development. Tyson held several senior positions over 14 years at GSK before joining Indivior, where he served as Vice President of Strategy and New Product Development, Senior Vice President of Sales and Marketing, and later President of Behavioral Health. During his time at Indivior, he oversaw the successful launch of SUBLOCADE®, a long-acting injectable therapy for opioid addiction, and contributed to 17 consecutive quarters of double-digit growth.

More recently, Tyson has worked within the growing field of neuroplastic therapies for psychiatric conditions, contributing at an executive level to companies such as Transcend Therapeutics, which recently announced a major partnership valued at $700 million with Otsuka.

NRx is currently advancing multiple programs alongside its pending ANDA for preservative-free ketamine. The company is preparing a New Drug Application under Fast Track designation for intravenous ketamine (NRX-100) aimed at treating patients with severe depression, including those experiencing suicidal ideation. Additionally, the company is developing NRX-101, its D-Cycloserine-based therapy designated as a Breakthrough Therapy. This medicine is being advanced as a neuroplastogen to enhance the effectiveness of Transcranial Magnetic Stimulation for depression and suicidality, in collaboration with Professor Joshua Brown, MD, PhD, NRx’s newly appointed Chief Medical Innovation Officer.

In his role as Chief Commercial Officer, Tyson will be responsible for establishing and leading market access, distribution, sales, and marketing operations. These efforts will support the commercialization of upcoming regulatory submissions and future psychiatric pipeline assets designed to address significant unmet needs in serious mental illness.

Dr. Jonathan C. Javitt, CEO and Chairman of NRx, expressed strong confidence in Tyson’s appointment, noting his longstanding commitment to improving the lives of people with serious mental health conditions and his proven leadership in building effective commercial organizations. He stated that Tyson’s expertise will play a vital role as NRx prepares for the expected launches of its portfolio of innovative therapies.